First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study Meeting Abstract
| Authors: | Voss, M. H.; Gurney, H.; Atduev, V.; Suárez, C.; Climent, M. A.; Pook, D. W.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; Stus, V.; Ferguson, T.; Wiechno, P.; Gokmen, E.; Lacombe, L.; Gedye, C.; Burgents, J. E.; Sharma, M.; Cornell, J.; Albiges, L. |
| Abstract Title: | First-line pembrolizumab plus lenvatinib for non-clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study |
| Meeting Title: | 2024 ASCO Genitourinary Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 42 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2024 Jan 25-27 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2024-02-01 |
| Language: | English |
| ACCESSION: | WOS:001266676900102 |
| DOI: | 10.1200/JCO.2024.42.4_suppl.2 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 2 -- Source: Wos |
